Wolverine Blend
Status
No approved product. No FDA-approved labeling exists for either component or the combination. In 2023 the FDA placed BPC-157 in Category 2 of its interim 503A categories, an enforcement category for substances that may present significant safety risks, not a statutory ban.
What it is
A community name for a BPC-157 and TB-500 combination vial.
What published research measured
Combines BPC-157 with the thymosin beta-4 derivative usually sold as TB-500, on the reasoning that one acts on angiogenesis and tendon healing and the other on actin dynamics and cell migration. Both components' evidence bases are described in their own entries and both are predominantly preclinical, with BPC-157's large rodent literature and thymosin beta-4's ophthalmic trial record neither of them supporting systemic musculoskeletal repair in healthy humans. No blend in this category has been studied as a blend. Trial evidence, where it exists, was generated on single agents given alone; no published study of the combination for interaction, additive adverse effects or altered pharmacokinetics was identified in the sources reviewed for this entry. Two practical consequences follow. A multi-compound vial is a compounded preparation, so the stability of each component in the presence of the others, and over the life of the vial, is generally unstudied. If a reaction occurs, multiple components make it difficult to attribute it to one of them, which is one reason clinical pharmacology usually introduces agents one at a time. Both components are prohibited in sport at all times.
Source
Not tied to a single designated source; see the published research on this molecule
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.